Want to see SION full AI Analyst Report?
SION Stock Chart & Stats
$6.17
$1.64(3.72%)
At close: 4:00 PM EDT
$6.17
$1.64(3.72%)
Day’s Range― - ―
52-Week Range$4.01 - $54.97
Previous CloseN/A
Volume654.94K
Average Volume (3M)433.16K
Market Cap
$278.96M
Enterprise Value$1.78K
Total Cash (Recent Filing)$211.03M
Total Debt (Recent Filing)$8.07M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 11, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding45,212,400
10 Day Avg. Volume474,586
30 Day Avg. Volume433,158
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.17Price Target Upside145.81% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage and substantial equity provide financial flexibility during clinical development. This reduces debt-service pressure and gives Sionna more capacity to fund research, manage setbacks, and pursue strategic options.
Cash ResourcesA sizeable cash balance supports continued pipeline development and allows management to preserve capital while reassessing programs. It may extend operating capacity and improve negotiating flexibility with potential strategic partners.
Phase 1 Combination DataPositive Phase 1 safety and pharmacokinetic results provide clinical validation for the SION-451 combination strategy. The preferred dual regimen gives the pipeline a clearer development focus despite the setback to SION-719.
Bears Say
Pre-Revenue ModelSionna has no product revenue and remains dependent on clinical progress before establishing a commercial business. Widening losses increase the importance of successful trials, regulatory advancement, and future financing or partnering.
Negative Cash GenerationSustained and increasing cash burn means operations are not self-funding. Even with substantial reserves, continued research and clinical work will consume capital, creating longer-term dependence on cash balances, equity financing, or collaboration proceeds.
Phase 2a SetbackThe failed Phase 2a endpoint removes a development path for SION-719 as an add-on to current standard care. This narrows the near-term pipeline and increases reliance on the earlier-stage SION-451 program for future clinical validation.
Sionna Therapeutics, Inc. News
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $4.01 and its highest was $54.97 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $278.96M.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
Sionna Therapeutics, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.66 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$0.01.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate is -0.64.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 45,212,400 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went up 4.795%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sionna Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.17 (145.81% Upside)
$15.17 (145.81% Upside)
Blogger Sentiment
Bullish
SION Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 265.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.54%
Trailing 12-Months
Company Description
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
SION Stock 12 Month Forecast
Average Price Target
$15.17
▲(145.81% Upside)
Technical Analysis
Sarepta Therapeutics
―
Intellia Therapeutics
―
Stoke Therapeutics
―
Beam Therapeutics
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
33.56% Insiders
9.59% Mutual Funds
12.57% Other Institutional Investors
37.16% Public Companies and
Individual Investors